(WHO) WHO & Hypertension [ (2021). Available from: https://www.who.int/news-room/fact-sheets/detail/hypertension
Albrecht, S. et al. Age-related comorbidities and mortality in people living with HIV in rural Tanzania. AIDS (London England). 33 (6), 1031–1041 (2019).
Brennan, A. T. et al. Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa. PLOS ONE. 13 (10), e0204020 (2018).
Pourcher, V., Gourmelen, J., Bureau, I. & Bouee, S. Comorbidities in people living with HIV: an epidemiologic and economic analysis using a claims database in France. PLOS ONE. 15 (12), e0243529 (2020).
Chhoun, P. et al. High prevalence of non-communicable diseases and associated risk factors amongst adults living with HIV in Cambodia. PLOS ONE 12(11):e0187591. (2017).
Baekken, M., Os, I., Sandvik, L. & Oektedalen, O. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. Journal of Hypertension 26(11):2126–2133. (2008).
Vecchiet, J. et al. Antihypertensive and metabolic effects of Telmisartan in hypertensive HIV-Positive patients. Antiviral Therapy 16(5):639–645. (2011).
Xu, Y., Chen, X. & Wang, K. J. J. A. S. H. Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis. Journal of the American Society of Hypertension 11(8):530–540. (2017).
Gonah, L., Moodley, I., Hlongwana, K. W. J. A. J. P. H. C. & Medicine, F. Prevalence of diabetes mellitus and hypertension in people living with human immunodeficiency virus on antiretroviral therapy in Gweru district. Zimbabwe 12 (1), 1–6 (2020).
Kagaruki, G. B. et al. Magnitude and risk factors of non-communicable diseases among people living with HIV in tanzania: a cross sectional study from Mbeya and Dar Es Salaam regions. 14:1–9. (2014).
Mogaka, J. N. et al. Prevalence and factors associated with hypertension among adults with and without HIV in Western Kenya. PLoS One 17(1):e0262400. (2022).
Hyle, E. P. et al. The association between HIV and atherosclerotic cardiovascular disease in sub-Saharan africa: a systematic review. BMC Public Health 17:1–15. (2017).
Sander, L. D. et al. Hypertension, cardiovascular risk factors and antihypertensive medication utilisation among HIV-infected individuals in R Akai. U Ganda. 20 (3), 391–396 (2015).
Memiah, P. et al. Hypertension and associated inflammatory markers among HIV-infected patients in Tanzania. Journal of Interferon & Cytokine Research 41(8):291–301. (2021).
Lukas, K., Markos, E., Belayneh, F. & Habte, A. The magnitude of hypertension and associated factors among clients on highly active antiretroviral treatment in Southern ethiopia, 2020: A hospital-based cross-sectional study. PLOS ONE. 16 (10), e0258576 (2021).
Gebrie, A. Hypertension among people living with human immunodeficiency virus receiving care at referral hospitals of Northwest ethiopia: A cross-sectional study. PLOS ONE. 15 (8), e0238114 (2020).
Sewale, Y., Afenigus, A. D., Haile, D. & Shiferaw, W. S. Magnitude of hypertension and associated factors among human immunodeficiency virus positive adults receiving Anti-Retroviral therapy at Debre Markos referral hospital (2020)., Northwest, Ethiopia. HIV/AIDS (Auckland, NZ). HIV AIDS (Auckl) 12:629–637 .
Lackland, D. T., Keil, J. E., Gazes, P. C., Hames, C. G. & Tyroler, H. A. Outcomes of black and white hypertensive individuals after 30 years of follow-up. Clin. Experimental Hypertens. (New York NY: 1993). 17 (7), 1091–1105 (1995).
Dillon, D. G. et al. Association of HIV and ART with cardiometabolic traits in sub-Saharan africa: a systematic review and meta-analysis. Int J Epidemiol 42(6):1754–1771. (2013).
Musekwa, R., Hamooya, B. M., Koethe, J. R., Nzala, S. & Masenga, S. K. J. P. A. M. J. Prevalence and correlates of hypertension in HIV-positive adults from the Livingstone central hospital. Zambia 39(1), 237. (2021).
Jemal, M. A review of dolutegravir-associated weight gain and secondary metabolic comorbidities. SAGE Open Med 12:20503121241260613. (2024).
Goldberg, R. N., Kania, A. T., Michienzi, S. M., Patel, M. & Badowski, M. E. J. J. I. A. P. A. C. Weight gain in incarcerated individuals living with HIV after switching to integrase strand inhibitor-based therapy. J Int Assoc Provid AIDS Care 20:2325958221996860. (2021).
Leggio, M. et al. The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins. Hypertens Res 40(12):947–963. (2017).
Kamal, P. & Sharma, S. J. J. E. S. SUN-187 dolutegravir causing diabetes. ;3(Supplement_1):SUN-187. (2019).
Kigongo, V. J. et al. Dyslipidemia among adult people living with HIV on dolutegravir – based antiretroviral therapy at a private tertiary hospital in kampala, uganda: burden and determinants. BMC Infect. Dis. 24 (1), 53 (2024).
Petrie, J. R., Guzik, T. J. & Touyz, R. M. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can. J. Cardiol. 34 (5), 575–584 (2018).
Kasoma Mutebi, R. et al. Prevalence of and factors associated with hypertension among adults on Dolutegravir-Based antiretroviral therapy in uganda: A cross sectional study. Integr. Blood Press. Control. 16, 11–21 (2023).
Lartey, M. et al. Hypertension among cohort of persons with human immunodeficiency virus initiated on a Dolutegravir-Based antiretroviral regimen in Ghana. Open. Forum Infect. Dis. 11 (3), ofae061 (2024).
FMoHo, E. J. G. W. H. O. National consolidated guidelines for comprehensive HIV prevention, care and treatment. (2020).
Organization, W. H. STEPwise approach to NCD risk factor surveillance (STEPS) Geneva: World Health Organization; [ (2012). Available from: https://www.who.int/teams/noncommunicable-diseases/surveillance/systems-tools/steps
Nuttall, F. Q. Body mass index: obesity, BMI, and health: A critical review. Nutr. Today. 50 (3), 117–128 (2015).
Consultation WEJRoaWECGWHO. Waist circumference and waist-hip ratio. 2008:8–11. (2008).
Williams, B. et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur. Heart J. 39 (33), 3021–3104 (2018).
Beyene Kassaw, A., Tezera Endale, H., Hunie Tesfa, K. & Derbew Molla, M. Metabolic syndrome and its associated factors among epileptic patients at Dessie comprehensive specialized hospital, Northeast ethiopia; a hospital-based comparative cross-sectional study. PLoS One. 17 (12), e0279580 (2022).
EPH A. On Alcohol, Substance, Khat and Tobacco. 22nd Annual Conference of EPHAApril 2012.
Tesfaye, F., Byass, P., Wall, S., Berhane, Y. & Bonita, R. Association of smoking and Khat (Catha Edulis Forsk) use with high blood pressure among adults in addis ababa, ethiopia, 2006. Prev. Chronic Dis. 5 (3), A89 (2008).
Manual FMoHJP. National Comprehensive HIV Prevention, Care and Treatment Training for Health care Providers. :1-123. (2018).
Assogba, C. O. et al. Prevalence and associated factors of hypertension among people living with HIV/AIDS on antiretroviral therapy in benin’s National teaching hospital. Sci. Rep. 14 (1), 17035 (2024).
Hirigo, A. T., Yilma, D., Astatkie, A. & Debebe, Z. The association between dolutegravir-based antiretrovirals and high blood pressure among adults with HIV in Southern ethiopia: a cross-sectional study. Ther Adv Infect Dis 11:20499361241306942. (2024).
Mulugeta, H. et al. Incidence and Predictors of Hypertension Among HIV Patients Receiving ART at Public Health Facilities, Northwest Ethiopia: A One-Year Multicenter Prospective Follow-Up Study. HIV/AIDS (Auckland, NZ). ;13:889–901. (2021).
Venter, W. (ed) Risks of hypertension with first-line dolutegravir and tenofovir alafenamide in the NAMSAL and ADVANCE trials-OALBB05. 12th IAS Conference on HIV Science Brisbane, Australia; (2023).
Mbuthia, G. W., Magutah, K. & McGarvey, S. T. The prevalence and associated factors of hypertension among HIV patients. Int. J. Hypertens. 2021 (1), 5544916 (2021).
Denu, M. K. I., Revoori, R., Buadu, M. A. E., Oladele, O. & Berko, K. P. Hypertension among persons living with HIV/AIDS and its association with HIV-related health factors. AIDS Res. Therapy. 21 (1), 5 (2024).
Mwakyandile, T. M. et al. Hypertension and traditional risk factors for cardiovascular diseases among treatment Naïve HIV- infected adults initiating antiretroviral therapy in urban Tanzania. BMC Cardiovasc. Disord. 23 (1), 309 (2023).
Tesfa, E. & Demeke, D. Prevalence of and risk factors for hypertension in ethiopia: A systematic review and meta-analysis. Health Sci. Rep. 4 (3), e372 (2021).
Dubey, R. K., Oparil, S., Imthurn, B. & Jackson, E. K. Sex hormones and hypertension. Cardiovascular. Res. 53 (3), 688–708 (2002).
Reckelhoff, J. F. J. H. Gender differences in the regulation of blood pressure. Hypertension 37(5):1199–1208. (2001).
Getahun, Z., Azage, M., Abuhay, T. & Abebe, F. Comorbidity of HIV, hypertension, and diabetes and associated factors among people receiving antiretroviral therapy in Bahir Dar City. Ethiopia J. Comorbidity. 10, 2235042×19899319 (2020).
McGettrick, P., Alvarez Barco, E. & Mallon, P. W. (eds) Ageing with HIV (MDPI, 2018).
Tsuro, U., Oladimeji, K. E., Pulido-Estrada, G. A. & Apalata, T. R. Risk factors attributable to hypertension among HIV-Infected patients on antiretroviral therapy in selected rural districts of the Eastern cape province, South Africa. Int. J. Environ. Res. Public Health 19(18). (2022).
Uwanyirigira, D. et al. Prevalence and factors associated with hypertension among HIV positive patients on antiretroviral therapy: A Hospital-Based Cross-Sectional study in Rwanda. Vasc. Health Risk Manag. 19, 857–870 (2023).
Badacho, A. S. & Mahomed, O. H. Prevalence of hypertension and diabetes and associated risk factors among people living with human immunodeficiency virus in Southern Ethiopia. Front. Cardiovasc. Med. 10, 1173440 (2023).
Haile, M., Degelo, T., Adilo, T. M., Adem, F. M. & Gidisa, B. Prevalence of Hypertension and Its Associated Factors Among Adults Living with HIV on Antiretroviral Treatment in Selected Public Hospitals in Addis Ababa, Ethiopia. HIV/AIDS (Auckland, NZ). ;16:109 – 22. (2024).
Tozawa, M. et al. Family history of hypertension and blood pressure in a screened cohort. Hypertens Res 24(2):93–98. (2001).
Harimenshi, D., Niyongabo, T., Preux, P. M., Aboyans, V. & Desormais, I. Hypertension and associated factors in HIV-infected patients receiving antiretroviral treatment in burundi: a cross-sectional study. Sci. Rep. 12 (1), 20509 (2022).
Ferrara, D., Montecucco, F., Dallegri, F. & Carbone, F. Impact of different ectopic fat depots on cardiovascular and metabolic diseases. J. Cell. Physiol. 234 (12), 21630–21641 (2019).
Goodpaster, B. H. et al. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. Jama 304 (16), 1795–1802 (2010).
Menard, A. et al. effect? Dolutegravir and weight gain: an unexpected bothering side. AIDS 31(10):1499–1500. (2017).
Zewudie, B. T. et al. The magnitude of undiagnosed hypertension and associated factors among HIV-positive patients attending antiretroviral therapy clinics of Butajira general hospital, gurage zone, Southern Ethiopia. SAGE Open. Med. 10, 20503121221094454 (2022).
Fiseha, T., Belete, A. G., Dereje, H. & Dires, A. Hypertension in HIV-Infected patients receiving antiretroviral therapy in Northeast Ethiopia. Int. J. Hypertens. 2019, 4103604 (2019).
Tatsumi, Y. et al. SAKU STUDY 39:e15–e6. (2021).
Tegegne, K. D. et al. Prevalence and factors associated with hypertension among peoples living with HIV in East africa, a systematic review and meta-analysis. BMC Infect. Dis. 23 (1), 724 (2023).
Cheung, B. M. & Li, C. Diabetes and hypertension: is there a common metabolic pathway? Curr. Atheroscler. Rep. 14 (2), 160–166 (2012).
